who年龄标准:求助翻译高手!!

来源:百度文库 编辑:查人人中国名人网 时间:2024/04/29 07:15:09
A more detailed understanding of the pathogenesis of human obesity may ultimately guide treatment of affected individuals. Obesity that results from reduced melanocortins, for example, might respond well to administration of melanocortin-receptor agonists, if and when they become available in a clinical setting. Evidence for this is provided in a recent study of POMC-knockout mice, in which obesity was reversed by administration of an MC4-receptor agonist113. Analogously, administering leptin to an obese human with genetic leptin deficiency reduced weight as markedly as it does in ob/ob mice114. Obesity that is associated with leptin resistance, however, may be common and would be unlikely to respond to leptin treatment unless the resistance can be overcome. Patients with defective melanocortin-receptor function, for example, seem unlikely to respond to therapy with either leptin or melanocortin-receptor agonists. These consideration sindicate that an expanded ability to diagnose the pathophysiological basis of human obesitywillhavedirectapplicationstoitstreatment.However,amultidrug regimen that targets multiplesites within the weight-regulatory system may be necessary to achieve and sustain weight loss in many individuals. The impressive effects of AGRP on food intake in rodents62,63 indicatethatitwarrantsevaluationinthetreatmentofconditionsassociatedwith excessive weight loss, including anorexia nervosa and wasting illness associatedwith AIDS or cancer. If AGRP proves ineffective in this context, it would in dicate that the pathogenesis of such conditions involves pathways additional to, and potentially downstream of, melanocortin-receptor activation. Such an outcome might therefore direct therapeutic strategies towards activation of other candidate anabolic (or inhibition of catabolic) effect or pathways. These considerations highlight the importance of clarifying the mechanisms that controlfood intake and energy homeostasis. Such information will help us to understand the pathogenesis of disorders at both ends of the body-weight spectrum, and is a probable prerequisite for their successful treatment. The enormous cost to human health attributable to these disorders emphasizes the need for a more complete understanding of this area.

有些看不懂,专业词汇太多拉

人类肥胖的 pathogenesis 的比较详细理解可能最后指导影响的个体治疗. 起因于减少的 melanocortins 的肥胖,举例来说,可能很好地回应 melanocortin- 受容器 agonists 的行政, 如果而且当他们在一个临床的设定中变成可得的时候. 对于这的证据被提供在一项 POMC- 击昏老鼠的最近研究中,在哪一肥胖被 MC4- 受容器的 agonist113 的行政颠倒了。 类似地,对一个肥胖的人类以遗传基因的 leptin 缺乏管理 leptin 像它在 ob/ ob mice114 中做一样的显着地减少了重量。 除非抵抗能被克服,否则与 leptin 抵抗有关的肥胖,然而,可能是通常的而且会不可能回应 leptin 治疗. 由于有缺陷的 melanocortin- 受容器的功能病人,举例来说,似乎不太可能回应治疗由于或 leptin 或 melanocortin- 受容器的 agonists. 这些考虑 sindicate 一种被扩大的能力诊断人类 obesitywillhavedirectapplicationstoitstreatment 。然而的 pathophysiological 基础, 在重量- 管制的系统里面对准 multiplesites 的 amultidrug 摄生可能是必需达成而且维持许多个体的减重. rodents62 ,过度的减重 63 indicatethatitwarrantsevaluationinthetreatmentofconditionsassociatedwith 的 AGRP 对食物摄?牧钊擞∠笊羁绦Ч?包括食欲减退 nervosa 而且浪费疾病 associatedwith 爱滋病或癌. 如果 AGRP 证明无效的在这上下文中,它会在如此情况的 pathogenesis 包括另外的路 dicate 中到,和可能地下游地,melanocortin- 受容器的使活动. 一个如此结果可能因此指示其他候选人合成代谢的 ( 或 catabolic 的禁止) 效果或路的对于使活动的治疗策略. 这些考虑加亮澄清机制那一个 controlfood 摄取和能源体内平衡的重要. 如此的数据将会帮助我们在两者身体- 重量的光谱结束了解混乱的 pathogenesis, 而且是他们的成功治疗的可能首要事物. 对归属于这些混乱的人类健康的巨大费用强调对这一个区域的比较完全理解的需要.

自己下个金山快译多好啊!
不用求人!
网上搜一下就是一大堆!
准确率还挺高的!